KeySine: dedicated to reproductive health, developing globally unique products — Yan Qianqian, general manager, KeySine Medical Technology (Jinan) Co., Ltd.

KeySine, as a leader in the treatment of female infertility caused by fallopian tube issues, has been dedicated to addressing challenges in women’s reproductive health since its establishment. Founded by a team of seasoned experts, including scientists, professionals from multinational corporations, and obstetricians and gynecologists pursuing full-time entrepreneurship, the company has pioneered globally unique products.

In women’s reproductive health, KeySine boasts three innovative platforms. Its Fallopian Tube Infertility Platform tackles the widespread issue of tubal infertility; the Postpartum Hemorrhage Management Platform features a "Me Better" product that matches U.S. competitors, primarily aimed at reducing postpartum bleeding risks; and the Biodegradable Uterine Barrier Platform, a domestic innovation, generates a variety of medical products derived from the same technical foundation.

Extensive clinical trials and practical applications demonstrate that KeySine’s products significantly improve conception rates for patients with hydrosalpinx-related infertility. To drive technological advancements and product upgrades, the company actively collaborates with leading medical institutions and experts globally, providing superior treatment options and services for more patients.

KeySine’s development in Jinan will proceed in three phases based on its plans. During 2024 to 2026, the company will establish production facilities, introduce domestically innovative fallopian tube intervention products, and cultivate the market. From 2027 to 2028, globally pioneering fallopian tube intervention products will be launched, accompanied by the development of a comprehensive gynecological intervention product line, including the world’s only fallopian tube intervention product series. From 2029 to 2030, efforts will focus on new product R&D and industrialization, upgrading the Shanghai headquarters to a global R&D hub while advancing product iteration and functional upgrades in Jinan to consolidate and expand market share.

In the future, KeySine aims to use high-end innovative medical device manufacturing as a lever to drive the concentrated development of related industries, including precision machining, advanced laser processing, precious metal processing, and precision injection molding. By fostering a synergistic ecosystem of research, industry, and medicine, the company seeks to inject fresh vitality into the construction and development of Jinan Medical Center.